1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/
Other news
RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013
Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...
GMP-certificate received
Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...
RTM added as distributor NeuraCeq®
Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...
First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
Interested in a collaboration?
Contact us to discuss the possibilities.
